Proactive Investors - Run By Investors For Investors

Pressure BioSciences expecting banner year for the company in 2018

Revenues for the firm's products and services increased 21% in the third quarter alone
pressure gauge
The firm speciaises in PCT (pressure cycling technology)

Pressure BioSciences Inc's (OTCMKTS:PBIO) boss Richard Schumacher expects 2018 to be a “banner year” for the firm.

In a 'Stock Day' podcast Schumacher ran through a number of aspects of recent progress, including that it had sold more PCT (pressure cycling technology) machines in the third quarter of 2017 than it had ever sold in a single quarter before.

Revenues for the firm's products and services increased 21% in that quarter alone, with consumable products increasing 158% - the largest increase in consumables the firm ever reported.

Schumacher also said a big multinational company, who was a customer, had also been working with Pressure to produce a software upgrade for its flagship Barocycler 2320EXTREME instrument.

Pressure believes this new instrument will now be "highly desirable" in its niche life sciences and pharmaceutical markets.

Also discussed was the newly established Center of Excellence in China, which will showcase three of the company's PCT instruments and many related consumable products.

"Being the first Center of Excellence in Asia, the company will focus on the Chinese biopharmaceutical and biological research markets where there is a large community of bioscience engineers and scientists and centers for biotechnology advancements," said Schumacher.

The firm's acquisition of BaroFold Inc had increased the IP (intellectual property) estate of the company by eight issued and several pending patents, and had allowed the company to offer a number of important new applications to its worldwide base of nearly 200 customers with PBIO instrumentation, he added.

Watch the Podcast HERE...

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

cannabis
October 18 2018
Sativa Investments has taken a big step towards becoming the UK's first seed to consumer medicinal cannabis business
1542204301_heart.jpg
November 14 2018
The goal of the program is to extend the visualization extracted from 2D ultrasound images and visualize 4D images
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara
Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use